These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 20369907)

  • 21. Change in cognitive function according to cholinesterase inhibitor use and amyloid PET positivity in patients with mild cognitive impairment.
    Pyun JM; Ryoo N; Park YH; Kim S
    Alzheimers Res Ther; 2021 Jan; 13(1):10. PubMed ID: 33402198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initial cognitive response to cholinesterase inhibitors and subsequent long-term course in patients with mild Alzheimer's disease.
    Droogsma E; van Asselt D; Diekhuis M; Veeger N; van der Hooft C; De Deyn PP
    Int Psychogeriatr; 2015 Aug; 27(8):1323-33. PubMed ID: 25779465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer's disease: a prospective, observational study of factors affecting survival time from admission to death.
    Wattmo C; Londos E; Minthon L
    BMC Neurol; 2016 Aug; 16(1):156. PubMed ID: 27581368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal Associations between Survival in Alzheimer's Disease and Cholinesterase Inhibitor Use, Progression, and Community-Based Services.
    Wattmo C; Londos E; Minthon L
    Dement Geriatr Cogn Disord; 2015; 40(5-6):297-310. PubMed ID: 26335053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease.
    Diniz BS; Pinto JA; Gonzaga ML; Guimarães FM; Gattaz WF; Forlenza OV
    Eur Arch Psychiatry Clin Neurosci; 2009 Jun; 259(4):248-56. PubMed ID: 19224111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
    Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
    Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
    Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
    Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cumulative Anticholinergic Burden and its Predictors among Older Adults with Alzheimer's Disease Initiating Cholinesterase Inhibitors.
    Talwar A; Chatterjee S; Sherer J; Abughosh S; Johnson M; Aparasu RR
    Drugs Aging; 2024 Apr; 41(4):339-355. PubMed ID: 38467994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rivastigmine for Alzheimer's disease.
    Birks JS; Grimley Evans J
    Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Randomized Placebo-Controlled Discontinuation Study of Cholinesterase Inhibitors in Institutionalized Patients With Moderate to Severe Alzheimer Disease.
    Herrmann N; O'Regan J; Ruthirakuhan M; Kiss A; Eryavec G; Williams E; Lanctôt KL
    J Am Med Dir Assoc; 2016 Feb; 17(2):142-7. PubMed ID: 26482056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cholinesterase inhibitor use in Alzheimer's disease: the EPIFARM-Elderly Project.
    Franchi C; Lucca U; Tettamanti M; Riva E; Fortino I; Bortolotti A; Merlino L; Pasina L; Nobili A
    Pharmacoepidemiol Drug Saf; 2011 May; 20(5):497-505. PubMed ID: 21432941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug persistency of cholinesterase inhibitors for patients with dementia of Alzheimer type in Korea.
    Ahn SH; Choi NK; Kim YJ; Seong JM; Shin JY; Jung SY; Park BJ
    Arch Pharm Res; 2015 Jun; 38(6):1255-62. PubMed ID: 25336105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of Cholinesterase Discontinuation during the First Year after Nursing Home Admission.
    Maclagan LC; Bronskill SE; Guan J; Campitelli MA; Herrmann N; Lapane KL; Hogan DB; Amuah JE; Seitz DP; Gill SS; Maxwell CJ
    J Am Med Dir Assoc; 2018 Nov; 19(11):959-966.e4. PubMed ID: 30262440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short-Term Response is not Predictive of Long-Term Response to Acetylcholinesterase Inhibitors in Old Age Subjects with Alzheimer's Disease: A "Real World" Study.
    Boccardi V; Baroni M; Smirne N; Clodomiro A; Ercolani S; Longo A; Ruggiero C; Bruni AC; Mecocci P
    J Alzheimers Dis; 2017; 56(1):239-248. PubMed ID: 27911323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can Persistence With Cholinesterase Inhibitor Treatment Lower Mortality and Health-Care Costs Among Patients With Alzheimer's Disease? A Population-Based Study in Taiwan.
    Ku LE; Li CY; Sun Y
    Am J Alzheimers Dis Other Demen; 2018 Mar; 33(2):86-92. PubMed ID: 29210284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching.
    Fisher A; Carney G; Bassett K; Dormuth CR
    Drugs Aging; 2017 Mar; 34(3):221-231. PubMed ID: 28138912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of rivastigmine or galantamine and risk of adverse cardiac events: a database study from the Netherlands.
    Kröger E; Berkers M; Carmichael PH; Souverein P; van Marum R; Egberts T
    Am J Geriatr Pharmacother; 2012 Dec; 10(6):373-80. PubMed ID: 23217530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease.
    Wattmo C; Blennow K; Hansson O
    BMC Neurol; 2020 Jan; 20(1):10. PubMed ID: 31918679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.